أفضل فحص شامل للغدة الدرقية التشخيص - توب -70 أطباء

مساعد. البروفيسور نوري ألبر شهباز طبيب ذو خبرة حاصل على تعليم طبي من جامعة اسطنبول ، كلية الطب جراح باشا ، وخبرة علمية وسريرية من كلية بايلور للطب وكلية الطب بجامعة تكساس. وهو متخصص في جراحة الغدد الصماء (أورام الغدة الدرقية ، والغدة الجار درقية ، والغدة الكظرية ، وأورام الغدد الصم العصبية) وقد أجرى أكثر من 2000 عملية جراحية ناجحة في هذا المجال. كما أنه متخصص في جراحات المناظير والجراحات طفيفة التوغل ، وكذلك في تنظير الجهاز الهضمي التشخيصي والعلاجي.

Was born in 1981 in Erzincan. After finishing Beşiktaş Atatürk Anadolu High School in 1999 entered Istanbul University Çapa, Faculty of Medicine. 

In 2005 I got his Master Degree and started as a practitioner at Yüksekova State Hospital. He got his Doctorate at Okmeydanı Training and Research Hospital in General Surgery department. As a General Surgery Specialist, he worked at Zonguldak Atatürk State Hospital for 5 years and at Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital for 3 years. 

Worked as an Assistant Professor at Istanbul Medipol University, Department of General Surgery. Currently working at Medipol University Pendik Hospital. 

Education:

2021 ULUDAĞ ÜNİVERSİTESİ, KULAK BURUN BOĞAZ HASTALIKLARI

2014 EGE ÜNİVERSİTESİ, TIP FAKÜLTESİ

Experience:

2023 - 2023 SAĞLIK BİLİMLERİ ÜNİVERSİTESİ SULTAN ABDÜLHAMİD HAN EĞİTİM VE ARAŞTIRMA HASTANESİ

2021 - 2022 ŞEHİT PROF.DR. İLHAN VARANK SANCAKTEPE EĞİTİM VE ARAŞTIRMA HASTANESİ

أستاذ الطب ، رئيس قسم الغدد الصماء والتمثيل الغذائي ، كلية الطب ، جامعة فيينا الطبية. خدم في العديد من المنظمات ، مثل قسم الغدد الصماء في الاتحاد الأوروبي للأخصائيين الطبيين والجمعية النمساوية لأمراض الغدد الصماء. أكثر من 300 منشور في مجلات محكمة تغطي مجالات البحوث السريرية والأساسية والترجمة.

الدكتور هو قائد فريق جراحة الغدد الصماء في جامعة فيينا الطبية. وهو متخصص في الجراحة العامة وجراحة البطن وحاصل على الدكتوراه في الطب (2005). قام بتنظيم العديد من المؤتمرات وهو عضو في العديد من الجمعيات الطبية. يشغل حاليًا منصب رئيس مجموعة العمل الجراحية للغدد الصماء في جامعة فيينا الطبية. حصل على جائزة Venia Docendi في عام 2017 وجائزة Sandoz لأبحاث الغدة الدرقية في عام 2010.

الدكتورة إيلانا إيتزاكوف اختصاصية الغدد الصماء في مركز إيخيلوف الطبي (مركز تل أبيب سوراسكي الطبي).

Education:

• Degree: Faculty of Medicine, Trakya University, 2009
• Medical Specialty: Internal Medicine, Bakırköy Dr. Sadi Konuk Training and Research Hospital, 2010-2014
• Specialist Doctor: Internal Medicine, Kanuni Sultan Süleyman Training and Research Hospital, 2014-2019
• Specialist Doctor: Internal Medicine, Turkish Hospital Internal Medicine Clinic, Qatar, 2019-2020
• Specialist Doctor: Internal Medicine, Istanbul Medipol University Hospital Mega Hospital Internal Medicine Department, 2020-2024
• Associate Professor Doctor: Internal Medicine, Istanbul Medipol University Medipol Acıbadem Regional Hospital, 2024-Present.

Roles in Projects:

Sub investigator (Assistant Researcher) in the SOUL Study: Cardiovascular Outcome Research of Semaglutide in Type 2 Diabetic Patients, approved by the Turkish Medicines and Medical Devices Agency on May 22, 2019.

Sub investigator (Assistant Researcher) in the international study “SCALE™ Insulin”: Efficacy and Safety of Liraglutide 3.0 mg in Overweight or Obese Patients with Type 2 Diabetes Treated with Basal Insulin (Study Code: NN8022-4272), conducted by Novo Nordisk A.Ş.

Subinvestigator (Assistant Researcher) in the international study NN5401-4266 StepByStep Intensification conducted by Novo Nordisk.

Assistant Researcher in the study "A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (SUSTAIN 11)" (2019-2020).

Assistant Researcher in the PIONEER 1 study: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.

Education and Experience

• 1992 - 1998, Gaziantep University, Faculty of Medicine
• 2002 – 2015, Cumhuriyet University, Faculty of Medicine, Department of Internal Medicine
• 2015 – 2024, Bağcılar Medipol Mega University Hospital
• 2024 – Present, Medipol Acıbadem Hospital

2014 : The world's first robotic oral thyroidectomy developed by Kim Hoon-yub

2011 ~ : Fellow of the International Society of Neuro Monitoring Research

2008 ~ : Permanent member of Korean Society of Endoscopic & Laparoscopic Surgeons

2008 ~ : Permanent member of Korean Society of Surgical Oncology

2008 ~ : Permanent member of the Asia Oceania Thyroid Association

2014 ~ : Research Professor, the Korean Society of Endoscopic & Laparoscopic Surgeons

2014 ~ : Member of planning Committee at the Korean Association of Thyroid and Endocrine Surgeons, member of the Medical Rights Advisory Committee

2012 ~ : Member of the International Surgery Research Forum

2015 ~ : Member of the American Thyroid Association

2015 ~ 2016: Research Professor, Division of Head and Neck Surgery, Johns Hopkins University School of Medicine, USA

Medical Interests 

Obesity 

Insulin resistance 

Diabetes 

Hypoglycemia (low sugar) 

Growth retardation and short stature 

Anorexia 

growth hormone deficiency 

Puberty problems (early puberty, delayed puberty, excessive hair growth, menstrual irregularity, polycystic ovary syndrome) 

Turner syndrome 

Thyroid diseases (Goiter, hypothyroidism, hyperthyroidism, Hashimoto’s disease, thyroid nodule) 

Sexual development disorders (small penis, undescended testis, gender ambiguity, hypospadias) 

Adrenal gland diseases (Congenital adrenal hyperplasia, Addison’s disease, Cushing’s syndrome) 

Bone and calcium metabolism diseases (rickets, vitamin D deficiency, osteoporosis) 

Education 

Bachelor’s - Master’s: Ankara University Faculty of Medicine (1998-2004) 

Ph.D. - Specialization in Medicine: Child Health and Diseases, Dr. Sami Ulus Gynecology and Childhood Health and Diseases Training and Research Hospital (2005-2010) 

Ph.D. - Minor specialization: Pediatric Endocrinology, Dokuz Eylul University Faculty of Medicine (2010-2013) 

Experience 

Child Health and Diseases Specialist Diyarbakır Children’s Hospital 2010 

Pediatric Endocrine Minor Assistant Dokuz Eylül University Medical Faculty Hospital 2010-2014 

Pediatric Endocrinology Specialist İzmir Tepecik Training and Research Hospital 2014-2015 

Assistant Professor Izmir Katip Celebi University Faculty of Medicine 2015-2016 

Associate Professor Izmir Katip Celebi University Faculty of Medicine 2016-2021 

Pediatric Endocrinology Associate Professor Ulus Liv Hospital 2021- Present 

Pediatric Endocrinology Associate Professor Vadistanbul Liv Hospital 2021- Present

Memberships 

Aegean Child Endocrine and Diabetes Association, Member, 2010 

Pediatric Endocrinology and Diabetes Association, Member, 2010 

Growing Child Association, Member, 2014 

European Society of Pediatric Endocrinology (ESPE), Member, 2016

Experience 

• 2016 - 2017

İSTİNYE UNIVERSITY FACULTY OF MEDICINE

• 2016 - 2017

Liv Hospital

• 2016 - 2017

Liv Hospital Ulus

• 2015 - 2016

Acıbadem Bodrum Hospital

• 2014 - 2015

Tatvan State Hospital

• 2013 - 2015

Tatvan State Hospital

• 2012 - 2013

CLEVELAND CLINIC

• 2007 - 2014

Dokuz Eylul University Faculty of Medicine

Education 

• 2013

DOKUZ EYLÜL UNIVERSITY FACULTY OF MEDICINE, FACULTY OF MEDICINE/DEPARTMENT OF SURGICAL MEDICAL SCIENCES/DEPARTMENT OF GENERAL SURGERY

• 2013

Dokuz Eylül University, General Surgery

• 2007

AKDENİZ UNIVERSITY, FACULTY OF MEDICINE

• 2007

International Peer-Reviewed Journal Articles:

Title: The impact of sarcopenia on morbidity and long-term survival among patients with peritoneal metastases of colorectal origin treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a 10-year longitudinal analysis of a single-center experience.

• Authors: AĞALAR CİHAN, SÖKMEN SELMAN, ARSLAN ÖZŞAHİN NACİYE ÇİĞDEM, ALTAY CANAN, BAŞARA AKIN IŞIL, CANDA ARAS EMRE, OBUZ FUNDA
• Journal: Techniques in Coloproctology
• Year: 2020
• Volume: 24(4)
• Pages: 301-308
• DOI: 10.1007/s10151-020-02159-z
• Publication Number: 6776368

Title: Randomized controlled trial of 8 weeks’ vs 12 weeks’ interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer.

• Authors: Terzi Cem, Bingül Mustafa, ARSLAN NACİYE ÇİĞDEM, ÖZTÜRK ERSİN, CANDA ARAS EMRE, IŞIK ÖZGEN, YILMAZLAR AHMET TUNCAY, OBUZ FUNDA, Görken Birkay, KURT MERAL, ÜNLÜ ŞADİYE MEHTAT, UĞRAŞ NESRİN, Kanat Özkan, ÖZTOP İLHAN
• Journal: Colorectal Disease
• Year: 2020
• Volume: 22(3)
• Pages: 279-288
• DOI: 10.1111/codi.14867
• Publication Number: 6012919

Title: The effect of fibrin glue in preventing staple-line leak after sleeve gastrectomy: an experimental study in rats.

• Authors: ÖZDENKAYA YAŞAR, OLMUŞÇELİK OKTAY, BASIM PELİN, SAKA BURCU, ARSLAN NACİYE ÇİĞDEM
• Journal: Acta Cirurgica Brasileira
• Year: 2019
• Volume: 34(8)
• Publication Number: 5242669

Title: Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy.

• Authors: CANDA ARAS EMRE, ARSLAN NACİYE ÇİĞDEM, Terzi Cem, Sokmen Selman, YAVUZŞEN TUĞBA, Ozkardesler Sevda, Unlu Mehtat, OBUZ FUNDA, FÜZÜN MEHMET
• Journal: World Journal of Surgical Oncology
• Year: 2018
• Volume: 16(1)
• Pages: 70-74
• DOI: 10.1186/s12957-018-1369-7
• Publication Number: 4863133

Title: Magnetic resonance-based pelvimetry and tumor volumetry can predict surgical difficulty and oncologic outcome in locally advanced mid–low rectal cancer.

• Authors: Atasoy Gulsen, ARSLAN NACİYE ÇİĞDEM, Elibol Funda, SAĞOL ÖZGÜL, OBUZ FUNDA, SÖKMEN SELMAN
• Journal: Surgery Today
• Year: 2018
• Volume: 48(12)
• Pages: 1040-1051
• DOI: 10.1007/s00595-018-1690-3
• Publication Number: 4863005

Title: Is advanced age a hesitation for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer?

• Authors: Terzi Cem, Sokmen Selman, ARSLAN NACİYE ÇİĞDEM, Ozkardesler Sevda, DURAL CEMIL, OBUZ FUNDA, CANDA ARAS EMRE, GÖKTÜRK ÜMIT KELEŞTEN
• Journal: International Journal of Surgery
• Year: 2018
• Volume: 51
• Pages: 156-160
• DOI: 10.1016/j.ijsu.2018.01.010
• Publication Number: 4855751

Contributions to Conferences:

Title: Outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: A single-center experience.

• Authors: CANDA ARAS EMRE, Sokmen Selman, Terzi Cem, ARSLAN NACİYE ÇİĞDEM, OBUZ FUNDA
• Conference: European Society of Surgical Oncology (ESSO) Congress
• Year: 2018
• Location: Budapest, Hungary

Title: Predictive factors for conversion to open surgery in laparoscopic colorectal surgery.

• Authors: ARSLAN NACİYE ÇİĞDEM, Terzi Cem, Sokmen Selman, CANDA ARAS EMRE, OBUZ FUNDA
• Conference: European Association for Endoscopic Surgery (EAES) Congress
• Year: 2017
• Location: Frankfurt, Germany

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)